All PlansPrior AuthHigh impact
Intravenous Immune Globulin (IVIG)
BCBS Tennessee·Allergy & Immunology, Hematology, Infectious Disease +7 more·Medical Policy
Effective date
Oct 31, 2026
We identified it
Aug 13, 2026
Summary
This is a comprehensive IVIG (Intravenous Immune Globulin) medical policy covering FDA-approved indications, compendial uses, documentation requirements, and coverage criteria for multiple immunodeficiency and autoimmune conditions. The policy establishes prior authorization requirements and clinical criteria for initial 6-month and re-authorization 12-month coverage periods. CRITICAL: This policy is marked 'Do Not Implement until 10/31/26' and is not yet effective.
Action Required
DEADLINE: By October 31, 2026, the billing and clinical teams must: (1) Update the prior authorization system to require documentation per this policy for all IVIG indications listed (Primary Immunodeficiency, Myasthenia Gravis, CIDP, Dermatomyositis, Polymyositis, LEMS, ITP, Parvovirus B19-PRCA, PANS/PANDAS, Stiff-person syndrome, Toxic shock syndrome, and toxic necrotizing fasciitis); (2) Configure the system to enforce the specific coverage criteria outlined for each condition, including pre-treatment laboratory thresholds (e.g., IgG < 500 mg/dL for CVID, platelet count documentation for ITP); (3) Implement tracking for initial 6-month authorizations versus re-authorization 12-month periods, with requirement for IgG trough level monitoring at least yearly for continuation; (4) Train prior authorization and billing staff on the extensive documentation requirements listed in the DOCUMENTATION section; (5) Update encounter templates and provider documentation checklists to capture all required clinical data (diagnostic test results, laboratory reports, immunoglobulin levels, vaccine response data, electrodiagnostic studies, antibody testing, clinical trial-and-failure records); (6) Establish internal workflow to verify compliance with coverage criteria before claim submission to prevent denials. The policy document is currently incomplete (cuts off mid-sentence on page 2 of 66) so final implementation details may be subject to change. DO NOT implement before 10/31/26. Monitor for policy updates as the implementation date approaches.